NORCURON Drug Patent Profile

When do Norcuron patents expire, and what generic alternatives are available?

Norcuron is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in NORCURON is vecuronium bromide. There are six drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the vecuronium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norcuron

A generic version of NORCURON was approved as vecuronium bromide by MEITHEAL on August 25^th, 1999.

Summary for NORCURON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	3
Patent Applications:	1,766
DailyMed Link:	NORCURON at DailyMed

Recent Clinical Trials for NORCURON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hebei Medical University Fourth Hospital	Phase 4
The First Teaching Hospital of Xinjiang Medical University	Phase 4
First Affiliated Hospital of Xinjiang Medical University	Phase 4

See all NORCURON clinical trials

US Patents and Regulatory Information for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984		DISCN	Yes	No
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992		DISCN	Yes	No

Expired US Patents for NORCURON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984	3,553,212
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992	4,237,126
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984	4,237,126
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-003	Jan 3, 1992	4,297,351
Organon Usa Inc	NORCURON	vecuronium bromide	INJECTABLE;INJECTION	018776-002	Apr 30, 1984	4,297,351

International Patents for NORCURON

See the table below for patents covering NORCURON around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	676708
Canada	1134813	2.beta., 16.beta.-BIS-PIPERIDINO-ANDROSTANES (2.beta., 16.beta.-BIS-PIPERIDINO-ANDROSTANES)
Finland	66881
Ireland	791593
New Zealand	191462	DERIVATIVES OF 2 ,16 -BIS-PIPERIDINO-3 -HYDROXY-5 -ANDROSTANE-3 -ESTERS
Norway	792810
United Kingdom	1138605

Market Dynamics and Financial Trajectory for Norcuron (Vecuronium Bromide)

Introduction to Norcuron (Vecuronium Bromide)

Norcuron, also known as vecuronium bromide, is a non-depolarizing neuromuscular blocking agent used in medical settings to facilitate skeletal muscle relaxation during surgery or mechanical ventilation. It is administered intravenously and is part of the broader neuromuscular blockade drugs market.

Global Neuromuscular Blockade Drugs Market Overview

The global neuromuscular blockade drugs market, which includes Norcuron, is projected to experience steady growth. As of 2023, the market size was valued at USD 5.23 billion and is expected to reach USD 7.44 billion by 2031, with a Compound Annual Growth Rate (CAGR) of 4.50% during the forecast period of 2024 to 2031[1].

Market Drivers

Several factors are driving the growth of the neuromuscular blockade drugs market, including:

Increasing Surgical Procedures

The rising number of surgical procedures globally, particularly in emerging economies, is a significant driver. This increase is fueled by better healthcare infrastructure and a growing geriatric population[1].

Advancements in Healthcare Infrastructure

Improvements in healthcare infrastructure and the introduction of novel neuromuscular blockade drugs are expected to further drive market growth. Research and development activities aimed at enhancing the safety and efficacy of these drugs are creating lucrative opportunities for market players[1].

Growing Demand in Critical Care Settings

The demand for neuromuscular blockade drugs in critical care settings is on the rise, contributing to the overall market growth. This is partly due to the need for muscle relaxation in intensive care units and during mechanical ventilation[1].

Market Segmentation

The neuromuscular blockade drugs market is segmented by type, drugs, end-users, and distribution channels.

By Type

• Depolarizing
• Non-depolarizing (which includes Norcuron)
• Others

By Drugs

• Succinylcholine
• Cisatracurium
• Mivacurium
• Doxacurium
• Rocuronium
• Atracurium
• Pancuronium
• Vecuronium (Norcuron)
• Others

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others[1].

Regional Analysis

North America

North America is expected to dominate the market due to its strong focus on research and development activities related to muscle relaxants and its well-established healthcare infrastructure. The presence of leading pharmaceutical companies and research institutions in this region further enhances its position[1].

Asia-Pacific

The Asia-Pacific region is anticipated to witness significant growth due to technological advancements, the development of novel molecules, and the growing prevalence of musculoskeletal disorders in countries like China and India. Government initiatives to improve healthcare infrastructure also contribute to this growth[1].

Financial Performance of Norcuron

Market Size and Revenue

While specific financial data for Norcuron alone is not readily available, the U.S. vecuronium bromide market was approximated to be around $10 million in 2010, according to IMS data[4].

Sales and Growth

The broader neuromuscular blockade drugs market, which includes Norcuron, is expected to grow significantly. However, for a more precise financial trajectory of Norcuron, one would need to look at the performance of its manufacturers and distributors. For instance, Sagent Pharmaceuticals, which launched vecuronium bromide for injection, would be a key player to monitor[4].

Competitive Landscape

The market for neuromuscular blockade drugs is competitive, with several major pharmaceutical companies involved. Companies like Merck, which has a significant presence in the pharmaceutical market, influence the overall dynamics through their research and development activities and market strategies[3].

Side Effects and Safety Considerations

Norcuron, like other neuromuscular blocking agents, has potential side effects such as low blood pressure and prolonged paralysis. Allergic reactions are rare, but it is crucial for healthcare providers to monitor patients closely. The safety profile of Norcuron is a critical factor in its market acceptance and usage[2].

Conclusion

The market for Norcuron, as part of the broader neuromuscular blockade drugs market, is poised for steady growth driven by increasing surgical procedures, advancements in healthcare infrastructure, and growing demand in critical care settings. The financial trajectory of Norcuron is tied to the overall performance of the neuromuscular blockade drugs market, with North America and the Asia-Pacific region expected to be key drivers.

Key Takeaways

• The global neuromuscular blockade drugs market is projected to grow from USD 5.23 billion in 2023 to USD 7.44 billion by 2031.
• Norcuron is a non-depolarizing neuromuscular blocking agent used in medical settings.
• Market growth is driven by increasing surgical procedures, advancements in healthcare infrastructure, and growing demand in critical care settings.
• North America and the Asia-Pacific region are expected to be significant markets.
• The financial performance of Norcuron is part of the broader market dynamics influenced by major pharmaceutical companies.

FAQs

Q: What is Norcuron used for?

Norcuron (vecuronium bromide) is used as part of general anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Q: What are the potential side effects of Norcuron?

Potential side effects include low blood pressure and prolonged paralysis. Allergic reactions are rare.

Q: Which regions are expected to dominate the neuromuscular blockade drugs market?

North America and the Asia-Pacific region are expected to be the dominant markets.

Q: What is the projected growth rate of the global neuromuscular blockade drugs market?

The market is projected to grow at a CAGR of 4.50% from 2024 to 2031.

Q: Who are some of the key players in the neuromuscular blockade drugs market?

Key players include major pharmaceutical companies such as those involved in research and development activities, and distributors like Sagent Pharmaceuticals.

Sources

1. Data Bridge Market Research: Global Neuromuscular Blockade Drugs Market Size, Demand & Research Report.
2. Wikipedia: Vecuronium bromide.
3. Merck: Merck Announces Fourth-Quarter and Full-Year 2020 Financial Results.
4. FiercePharma: Sagent Pharmaceuticals Launches Vecuronium Bromide For Injection.